MMP12 is a Potential Predictive and Prognostic Biomarker of Various Cancers Including Lung Adenocarcinoma
| Autor: | Guo-Sheng Li, Yu-Xing Tang, Wei Zhang, Jian-Di Li, He-Qing Huang, Jun Liu, Zong-Wang Fu, Rong-Quan He, Jin-Liang Kong, Hua-Fu Zhou, Gang Chen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Cancer Control, Vol 31 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1526-2359 10732748 |
| DOI: | 10.1177/10732748241235468 |
| Popis: | Objective This study sought to explore the clinical value of matrix metalloproteinases 12 ( MMP12 ) in multiple cancers, including lung adenocarcinoma (LUAD). Methods Using >10,000 samples, this retrospective study demonstrated the first pan-cancer analysis of MMP12 . The expression of MMP12 between cancer groups and their control groups was analyzed using Wilcoxon rank-sum tests. The clinical significance of MMP12 expression in multiple cancers was assessed using receiver operating characteristic curves, Kaplan–Meier curves, and univariate Cox analysis. A further LUAD-related analysis based on 4565 multi-center and in-house samples was performed to verify the findings regarding MMP12 in pan-cancer analysis partly. Results MMP12 mRNA is highly expressed in 13 cancers compared to their controls, and the MMP12 protein level is elevated in some of these cancers (e.g., colon adenocarcinoma) ( P < .05). MMP12 expression makes it feasible to distinguish 21 cancer tissues from normal tissues (AUC = 0.86). A high MMP12 expression is a prognosis risk factor in eight cancers, such as adrenocortical carcinoma (hazard ratio >1, P < .05). The elevated MMP12 expression is also a prognosis protective factor in breast-invasive carcinoma and colon adenocarcinoma (hazard ratio |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|